To the Editor:

We read with great interest the article on adapting childhood cancer services during the COVID‐19 pandemic from global pediatric oncology experts.[^1^](#pbc28462-bib-0001){ref-type="ref"}, [^2^](#pbc28462-bib-0002){ref-type="ref"} The document highlights the six most curable cancers with practical advice for their management during the COVID‐19 pandemic, and includes adaptations for low‐ to middle‐income countries (LMICs). While we share the broad consensus outlined here, we faced several unique challenges at our hospital---a large tertiary cancer care center in Mumbai, now at the epicenter of the outbreak in India‐ compelling us to take several steps to mitigate the impact of the pandemic, which may be of benefit to others affected similarly in healthcare settings closer to ours.

The Government of India declared one of the largest and most complete lockdowns in the world on March 25, 2020, which may have had an impact on slowing the first surge of COVID‐19. Well before this, our center anticipated a potential cancer‐care disaster, located as we are in a population‐dense urban setting with overstretched infrastructure and an unparalleled workload of over 60 000 new cases of cancer annually, including nearly 3000 children, more than 95% being from outside Mumbai. Measures were initiated 2 weeks prior to the lockdown aimed at reducing outpatient footfall and conservation of supportive care resources and staff, as already detailed elsewhere.[^3^](#pbc28462-bib-0003){ref-type="ref"}, [^4^](#pbc28462-bib-0004){ref-type="ref"}

Within this larger response, we tailored management of pediatric cancers to meet the twin objectives of retaining hard‐fought recent improvements in disease outcomes of largely curable malignancies,[^5^](#pbc28462-bib-0005){ref-type="ref"}, [^6^](#pbc28462-bib-0006){ref-type="ref"} while balancing resource constraints from disruption of services, and evolving strategies for the inevitable cancer with COVID‐19 patient surge. Our priority was to immediately reduce the average of 300 daily outpatient visits to pediatric cancer units by more than 50%. Screening at entrance gates was done by medical teams that dispensed advice and medication for low‐risk patients such as those on follow up or maintenance therapies without the patient needing to enter the premises, and they were later followed up telephonically. A comprehensive teleconsult facility was set up to prevent unwarranted visits by those due to follow up in the coming weeks from around the country. We achieved the targeted 50% reduction before the lockdown, which in turn led to travel disruptions preventing new cases reaching us. Despite these measures, 890 active cases were seen in the pediatric outpatient clinics with over 2900 clinic visits from March 21 to May 1, 2020, including 15 new cases.

To reduce the strain on supportive care resources such as disruptions in blood product supplies, we were able to fall back on several measures that had been successfully used earlier. These included low‐cost adaption of protocols that substituted high‐dose methotrexate, and oral metronomic chemotherapy (OMCT) used in curative settings such as maintenance, or as a bridge to definitive therapy, by giving time to ameliorate severe comorbidities or socioeconomic constraints with necessary interventions prior to the standard treatment. These strategies have consistently yielded us acceptable and often excellent outcomes.[^5^](#pbc28462-bib-0005){ref-type="ref"}, [^6^](#pbc28462-bib-0006){ref-type="ref"}, [^7^](#pbc28462-bib-0007){ref-type="ref"}, [^8^](#pbc28462-bib-0008){ref-type="ref"} We rolled out a comprehensive set of measures including these and similar adaptations, and summarized them for easy reference.[^9^](#pbc28462-bib-0009){ref-type="ref"} These guidelines helped us to successfully brace for the initial COVID‐19 surge, and a brief summary of the first seven cases of childhood cancer from among 59 COVID‐19 patients in 5 weeks from the first recorded case seen at our center is included (Table [1](#pbc28462-tbl-0001){ref-type="table"}). With recent publicly available data showing no signs of the first wave abating in Mumbai and other parts of India, we have updated our guidelines to adapt to the rapidly changing external and internal logistics and pandemic realities.

###### 

Clinical details and follow up of children with positive COVID‐19 test (n = 7)

  Serial number   Age (years)   Sex   Diagnosis                        Phase of treatment                                       Disease status        Reason for COVID‐19 testing   Symptoms at time of testing   Disease‐specific treatment   Treatment for COVID‐19   Status at last FU (days since positive test)
  --------------- ------------- ----- -------------------------------- -------------------------------------------------------- --------------------- ----------------------------- ----------------------------- ---------------------------- ------------------------ ----------------------------------------------
  1               4             F     SR B‐ALL                         Induction week 2                                         Not in remission      Contact                       None                          Chemotherapy continued       None                     Stable (16)
  2               13            F     LGG (optic pathway)              Post 2nd‐line chemotherapy (due for debulking surgery)   Progressive disease   Contact                       None                          Surgery awaited              None                     Stable (16)
  3               1             M     LGG (PA)                         Post week 13 VCR‐carboplatin                             Stable disease        Symptomatic                   Fever                         Next cycle deferred          Symptomatic              Stable (16)
  4               4             M     Undifferentiated sarcoma         Post \#3 IVA (induction chemotherapy)                    Response scan due     Symptomatic                   Fever                         Cycle 4 deferred             Symptomatic              Stable (16)
  5               7             M     HR B‐ALL                         Interim maintenance                                      In remission          Symptomatic                   Fever                         6‐MP continued               Symptomatic              Stable (14)
  6               4             F     HR neuroblastoma (postsurgery)   Due for auto‐HSCT                                        Metastatic CR         Symptomatic                   Fever                         Auto‐HSCT awaited            Symptomatic              Stable (11)
  7               2             F     HR hepatoblastoma                Post \#9 super‐PLADO                                     In remission          Symptomatic                   Fever                         Next cycle deferral likely   Symptomatic              Stable (5)

Abbreviations: 6‐MP, 6‐mercaptopurine; B‐ALL, B‐acute lymphoblastic leukemia; CR, complete remission; FU, follow up; HR, high risk; HSCT, hematopoietic stem cell transplant; IVA, ifosfamide/vincristine/dactinomycin; LGG, low‐grade glioma; PA, pilocytic astrocytoma; PLADO, platinum‐doxorubicin; SR, standard risk; VCR, vincristine.
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